Your session is about to expire
← Back to Search
Contrast-Enhanced Imaging for Liver Cancer (ACRIN6690 Trial)
N/A
Waitlist Available
Led By Christoph Wald, MD, PhD
Research Sponsored by American College of Radiology Imaging Network
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is looking at how well contrast-enhanced CT and MRI scans can detect and stage liver cancer in patients with chronic liver disease.
Eligible Conditions
- Hepatocellular Carcinoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Waitlisted with HCC-Exception PointsExperimental Treatment3 Interventions
Participants undergo CT and MRI every 90 days for the trial with iodinated contrast dye and motexafin gadolinium, during liver transplant wait listing. Possible Eovist-enhanced MRI substudy participation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Motexafin gadolinium
Not yet FDA approved
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,957 Previous Clinical Trials
41,111,647 Total Patients Enrolled
43 Trials studying Hepatocellular Carcinoma
5,662 Patients Enrolled for Hepatocellular Carcinoma
American College of Radiology Imaging NetworkLead Sponsor
39 Previous Clinical Trials
465,520 Total Patients Enrolled
Christoph Wald, MD, PhDPrincipal InvestigatorLahey Clinic Medical Center - Burlington
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Waitlisted with HCC-Exception Points
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.